Regulatory Lilly wins new FDA approval for eczema drug Ebglyss PharmaphorumLilly's Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent.Immunology & InflammationRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) Pharmaphorum Lilly’s Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent. Immunology & Inflammation Read full story Post navigation Previous: Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drugNext: Aquipta recommended by NICE for acute migraine treatment Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026